Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14007040 | 0.89 | KMT2A (0.51) | KMT2AMEN1MDM2ALDH1A1MAPT | |
| SCHEMBL12972568 | 0.89 | MEN1 (0.45) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL12873284 | 0.89 | LMNA (0.46) | KMT2AMEN1MDM2EPHX2ALDH1A1 | |
| SCHEMBL12555211 | 0.89 | KMT2A (0.47) | KMT2AMEN1MDM2EPHX2ALDH1A1 | |
| SCHEMBL20586242 | 0.88 | KMT2A (0.48) | KMT2AMEN1MDM2ALDH1A1MAPT | |
| SCHEMBL31749265 | 0.88 | KMT2A (0.54) | KMT2AMEN1MDM2ALDH1A1MAPT | |
| SCHEMBL27214060 | 0.88 | KMT2A (0.54) | KMT2AMEN1MDM2ALDH1A1MAPT | |
| SCHEMBL8410923 | 0.88 | KMT2A (0.45) | KMT2AMEN1MDM2EPHX2SMN1; SMN2 | |
| SCHEMBL17192730 | 0.88 | KMT2A (0.45) | KMT2AMEN1MDM2EPHX2SMN1; SMN2 | |
| SCHEMBL13379273 | 0.88 | KMT2A (0.42) | KMT2AMEN1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394341-B2 | Eptifibatide preparation method | CHENGDU SHENGNUO BIOTEC CO., LTD. (CN) | 2016-07-19 | — | — | US | disclosed |
| US-20150299261-A1 | EPTIFIBATIDE PREPARATION METHOD | CHENGDU SHENGNUO BIO TEC CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299261-A1 | EPTIFIBATIDE PREPARATION METHOD | RXFP1, OGFR, RXFP3 | KMT2A 3326/4885MEN1 4111/4885MDM2 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.